當前位置：首頁 SCI期刊 SCIE期刊醫學中科院2區期刊介紹(非官網)

Genes And DiseasesSCIE

國際簡稱：Genes and Diseases 參考譯名：基因與疾病

中科院分區
2區
CiteScore分區
Q1

基本信息：: ISSN：2352-3042; 是否OA：開放; 是否預警：否; TOP期刊：是

出版信息：: 出版地區：Netherlands; 出版商：Elsevier; 出版語言：English; 研究方向：Biochemistry, Genetics and Molecular Biology-Biochemistry

評價信息：: CiteScore指數：7.3; SJR指數：1.446; SNIP指數：1.228

發文數據：: Gold OA文章占比：0.00%; 研究類文章占比：0.00%

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數據中科院SCI分區發文數據常見問題

英文簡介Genes And Diseases期刊介紹

Genes&Diseases, sponsored by Chongqing Medical University, is an all English open access (OA) journal that focuses on the combination of molecular medicine and translational medicine. Since its establishment in 2014, this journal has focused on the pathogenesis of human diseases and cutting-edge advances in precision medicine, timely publishing industry hotspots, and committed to publishing high-quality articles and reviews.

The magazine has a wide range of submissions, including but not limited to molecular biology, molecular genetics, cell biology, stem cell biology, developmental biology, gene regulation, epigenetics, cancer biology, immunity and infection, neuroscience, animal models, gene and cell therapy, and regenerative medicine. The journal aims to establish an advanced academic platform for international academic exchange and lead the forefront of disciplines.

期刊簡介Genes And Diseases期刊介紹

《Genes And Diseases》是一本醫學優秀雜志。致力于發表原創科學研究結果，并為醫學各個領域的原創研究提供一個展示平臺，以促進醫學領域的的進步。該刊鼓勵先進的、清晰的闡述，從廣泛的視角提供當前感興趣的研究主題的新見解，或審查多年來某個重要領域的所有重要發展。該期刊特色在于及時報道醫學領域的最新進展和新發現新突破等。該刊近一年未被列入預警期刊名單，目前已被權威數據庫SCIE收錄，得到了廣泛的認可。

該期刊投稿重要關注點：

預計審稿時間： 35 Weeks
國際TOP期刊
醫學
BIOCHEMISTRY & MOLECULAR BIOLOGY
SCIE
中科院2區
非預警

Cite Score數據（2024年最新版）Genes And Diseases Cite Score數據

CiteScore：7.3
SJR：1.446
SNIP：1.228

學科類別	分區	排名	百分位
大類：Medicine 小類：Genetics (clinical)	Q1	22 / 99	78%
大類：Medicine 小類：Biochemistry	Q2	129 / 438	70%
大類：Medicine 小類：Molecular Biology	Q2	150 / 410	63%
大類：Medicine 小類：Cell Biology	Q2	118 / 285	58%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標。反映出一家期刊近期發表論文的年篇均引用次數。CiteScore以Scopus數據庫中收集的引文為基礎，針對的是前四年發表的論文的引文。CiteScore的意義在于，它可以為學術界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標來評價。

歷年Cite Score趨勢圖

中科院SCI分區Genes And Diseases 中科院分區

中科院 2023年12月升級版 綜述期刊：否 Top期刊：否

大類學科	分區	小類學科	分區
醫學	2區	BIOCHEMISTRY & MOLECULAR BIOLOGY 生化與分子生物學 GENETICS & HEREDITY 遺傳學	2區 2區

中科院分區表 是以客觀數據為基礎，運用科學計量學方法對國際、國內學術期刊依據影響力進行等級劃分的期刊評價標準。它為我國科研、教育機構的管理人員、科研工作者提供了一份評價國際學術期刊影響力的參考數據，得到了全國各地高校、科研機構的廣泛認可。

中科院分區表 將所有期刊按照一定指標劃分為1區、2區、3區、4區四個層次，類似于“優、良、及格”等。最開始，這個分區只是為了方便圖書管理及圖書情報領域的研究和期刊評估。之后中科院分區逐步發展成為了一種評價學術期刊質量的重要工具。

歷年中科院分區趨勢圖

本刊中國學者近年發表論文

1、Cell cycle dysregulation with overexpression of KIF2C/MCAK is a critical event in nasopharyngeal carcinoma
Author: Zuo, Xiaofeng; Meng, Peixin; Bao, Yuxin; Tao, Chuntao; Wang, Yitao; Liu, Xianjun; Bu, Youquan; Zhu, Jiang

Journal: GENES & DISEASES. 2023; Vol. 10, Issue 1, pp. 212-227. DOI: 10.1016/j.gendis.2021.05.003
2、Androgen receptor inhibits the hair follicle induction potential of dermal papilla cells by binding with Tcf4 at the A574 binding site
Author: Yu, Nanlan; Hu, Tianxing; Yang, Haichao; Zhang, Lian; Zhu, Lin; Zhou, Xiaofang; Xiang, Fei; Yang, Xichuan; Li, Yuhong

Journal: GENES & DISEASES. 2023; Vol. 10, Issue 1, pp. 51-54. DOI: 10.1016/j.gendis.2022.04.015
3、Adipose-derived stem cells and obesity: The spear and shield relationship
Author: Yang, Hong; Li, Chaowei; Li, Yizhou; Tai, Ruiqing; Sun, Chao

Journal: GENES & DISEASES. 2023; Vol. 10, Issue 1, pp. 175-186. DOI: 10.1016/j.gendis.2021.09.004
4、Dynamic m6A-ncRNAs association and their impact on cancer pathogenesis, immune regulation and therapeutic response
Author: Yan, Yuanliang; Peng, Jinwu; Liang, Qiuju; Ren, Xinxin; Cai, Yuan; Peng, Bi; Chen, Xi; Wang, Xiang; Yi, Qiaoli; Xu, Zhijie

Journal: GENES & DISEASES. 2023; Vol. 10, Issue 1, pp. 135-150. DOI: 10.1016/j.gendis.2021.10.004
5、Pathogenic roles of long noncoding RNAs in melanoma: Implications in diagnosis and therapies
Author: Xiao, Yuai; Xia, Yu; Wang, Yuchong; Xue, Chunyu

Journal: GENES & DISEASES. 2023; Vol. 10, Issue 1, pp. 113-125. DOI: 10.1016/j.gendis.2021.08.0072352-3042
6、PCK1 dysregulation in cancer: Metabolic reprogramming, oncogenic activation, and therapeutic opportunities
Author: Xiang, Jin; Wang, Kai; Tang, Ni

Journal: GENES & DISEASES. 2023; Vol. 10, Issue 1, pp. 101-112. DOI: 10.1016/j.gendis.2022.02.010
7、Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials
Author: Song, Yanlin; Bi, Zhenfei; Liu, Yu; Qin, Furong; Wei, Yuquan; Wei, Xiawei

Journal: GENES & DISEASES. 2023; Vol. 10, Issue 1, pp. 76-88. DOI: 10.1016/j.gendis.2022.05.006
8、Liquiritigenin promotes osteogenic differentiation and prevents bone loss via inducing auto-lysosomal degradation and inhibiting apoptosis
Author: Qiu, Yu; Zhao, Yueyang; Long, Zhimin; Song, Aijia; Huang, Peng; Wang, Kejian; Xu, Ling; Molloy, David Paul; He, Guiqiong

Journal: GENES & DISEASES. 2023; Vol. 10, Issue 1, pp. 284-300. DOI: 10.1016/j.gendis.2021.06.008